Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Gap Open @ C$ 1.86

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 13, 2024 5:56pm

91 Views

Post# 36177488

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Gap Open @ C$ 1.86

PrECOG, LLC. ran ONCY's Bracelet-1 study, enrolling 18 medical centers, from Eastern, N,E and S.E USA. - from New York to Illinois to Florida. ONCY did not run the trial. These medical centers were those that Pfizer and Roche have regularly used in conducting their clinical studies. This notwithstanding, ONCY management needs involvement in the final interpretation of the data.

https://www.precogllc.org/

https://clinicaltrials.gov/study/NCT04215146?cond=breast%20cancer&intr=pelareorep&rank=3#locations

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages